DR. STANLEY R. ROTHSCHILD, M.D.

Plain English
This study looked at pediatric patients diagnosed with tenosynovial giant cell tumor (TGCT), a rare tumor that affects joints and tendons. Out of 1,278 patients in the registry, 122 were children, with most (73%) having the more aggressive form called diffuse TGCT. The researchers found that pediatric patients often faced delayed diagnoses and had a higher surgery rate compared to adults, highlighting the need for better education and treatment options for these young patients, as their quality of life is significantly impacted. Who this helps: This benefits pediatric patients with TGCT and their medical providers.

Plain English
This study looked at how tenosynovial giant cell tumors (TGCTs) are treated differently across the UK and aimed to create a more uniform approach to managing these tumors. Experts found that there were significant differences in how TGCTs were classified and handled, and they established clear definitions and guidelines for when patients should be referred to specialized medical teams. Standardizing these practices can lead to better treatment for patients with TGCTs and make sure they get the right care no matter where they live. Who this helps: This helps patients with tenosynovial giant cell tumors and their doctors.

Plain English
This study looked at patients with a specific type of cancer called gastrointestinal stromal tumors (GISTs) that have a mutation in the KIT gene. Researchers found that giving adjuvant imatinib (a targeted cancer therapy) after surgery significantly reduced the chances of the cancer coming back and improved overall survival rates. Specifically, patients who received imatinib had a 81% lower risk of recurrence or death compared to those who didn't, and their chances of surviving longer were also notably better. Who this helps: This research benefits patients with GISTs that have KIT exon 9 mutations, as well as their doctors who are treating them.

Plain English
This research paper looks at gastrointestinal stromal tumors (GISTs) and how genetic testing can improve diagnosis and treatment. Researchers found that understanding specific gene mutations, particularly in cases of SDH-deficient GISTs, is essential for better patient care. For instance, all patients with SDH-deficient GISTs should be monitored for other related tumors, regardless of their genetic testing results. Who this helps: This benefits patients with GISTs and healthcare providers by improving treatment strategies and ongoing care.

Plain English
This study looked at the experiences of patients with Tenosynovial Giant Cell Tumor (TGCT), a rare tumor that can hurt physical function and quality of life. Out of 497 patients worldwide, 71.4% had a diffuse type of TGCT, and many faced delays in diagnosis, with 32% waiting over 24 months after symptoms started. More than half of the patients had multiple surgeries, and 63% of those experienced recurrences, leading to significant impacts on employment for about 23% of the patients. Who this helps: This research helps patients with TGCT and their healthcare providers by highlighting the need for better diagnosis and treatment options.

Plain English
This study focused on advanced gastrointestinal stromal tumors (GIST), which often become resistant to the drug imatinib. Researchers found two distinct groups of tumors based on their resistance and identified six potential new drugs that could effectively target these resistant tumors, with linifanib showing significant tumor growth reduction in tests. This is important because it offers new treatment options for patients who no longer respond to imatinib. Who this helps: Patients with imatinib-resistant gastrointestinal stromal tumors.

Plain English
This study looked at how working together with patients and advocacy groups can improve care and research for sarcoma, a type of rare cancer. It found that collaborative initiatives like the Sarcoma European and Latin American Network and The Life Raft Group are successfully enhancing diagnosis and treatment outcomes for these patients. This matters because it shows that when the medical community joins forces with patients, they can tackle the unique challenges of sarcoma and make significant progress in health care. Who this helps: This helps sarcoma patients and their families, as well as doctors treating them.

Plain English
This study compared two cancer treatments for patients with advanced non-small cell lung cancer (NSCLC) who have a specific genetic mutation known as KRAS G12C. Researchers found that patients taking sotorasib experienced fewer side effects and maintained a better quality of life compared to those receiving docetaxel. Specifically, those on sotorasib reported significantly less severe pain and discomfort, and their quality of life scores improved while quality of life declined for those on docetaxel. Who this helps: This benefits patients with KRAS G12C-mutated advanced NSCLC, offering them a more tolerable treatment option.

Plain English
The study examined how genetic tests for cancer are reported in Switzerland, focusing on the differences among various hospitals. Researchers found 48 inconsistencies in how 68 reporting items were handled, which highlights the need for standardized reports to avoid confusion when patients change hospitals. The Swiss Society of Molecular Pathology has proposed clear recommendations for these reports, including necessary patient details and clinical relevance to improve understanding among medical professionals and prevent misinterpretations. Who this helps: This helps patients and their doctors by ensuring clear and consistent information in cancer reports.

Plain English
Researchers studied how well certain blood tests, called tumour markers, predict relapses in testicular cancer patients. They looked at data from 793 patients and found that while 8.9% had a proven relapse, only 43.6% of those had elevated tumour markers. Importantly, 15.6% had false-positive results, meaning the markers incorrectly indicated a problem; the most reliable marker (beta HCG) had only a 33.8% accuracy rate. Who this helps: This information benefits doctors and testicular cancer patients by improving the accuracy of follow-up tests.

Plain English
The Heart-to-Heart study is researching how a lifestyle education program can help lower blood pressure in African American adults who struggle to control it. The study involves around 272 participants from 34 churches and features sessions on diet, lifestyle, and financial education over 12 months. Initial findings are expected to show changes in blood pressure, medication adherence, and overall health knowledge, which are important for improving the health of this community. Who this helps: This helps African American patients dealing with high blood pressure.

Plain English
Researchers studied the impact of molecular testing on patients with Gastrointestinal Stromal Tumors (GIST). They found that patients who received molecular testing lived longer, with an average survival of 14.7 years compared to 12.7 years for those without testing. Additionally, among patients receiving the first line of treatment, those with testing survived an average of 8.9 years versus 5.9 years for those without. This is important because identifying mutations can lead to more effective treatments, potentially improving patient outcomes significantly. Who this helps: This benefits GIST patients and their doctors by guiding treatment decisions.

Plain English
This research looks at a new treatment plan for patients with muscle-invasive bladder cancer (MIBC). It combines a form of immunotherapy with chemotherapy to improve cancer response rates. Specifically, the treatment uses a version of BCG therapy alongside cisplatin and gemcitabine, followed by surgery and ongoing immunotherapy for a total of 13 cycles. The main goal is to achieve complete remission, with additional goals including overall survival and assessing any side effects. Who this helps: This study benefits patients with muscle-invasive bladder cancer.

Plain English
This study looked at how tumor immunotherapy works and the side effects it can cause. Researchers found that while immune checkpoint inhibitors have improved survival rates for many patients, not everyone responds well, and some experience significant side effects. Understanding how these side effects happen can help doctors find better prevention and treatment options. Who this helps: This benefits patients undergoing immunotherapy and their doctors.

Plain English
The study looked at why patients with gastrointestinal stromal tumors (GIST) have low rates of genetic testing, which can help inform their treatment. Out of nearly 1,000 patients and caregivers surveyed, 80% reported receiving mutational testing, significantly more than the 26.7% in the overall GIST community. Importantly, one in four patients (25%) found that this testing led to a change in their treatment plan, which can improve their health outcomes. Who this helps: This helps GIST patients and their doctors make better treatment decisions.

Plain English
This study examined how traditional chemotherapy affects the immune environment in tumors of patients with non-small-cell lung cancer (NSCLC). Researchers analyzed tumor samples from 100 patients before treatment and 33 samples after chemotherapy, discovering that chemotherapy reduced the expression of key immune genes in 29 matched patients. Specifically, they found significant decreases in several important genes that help the immune system target cancer, indicating that chemotherapy weakens the immune response against tumors as the disease progresses. Who this helps: This findings help doctors understand the impact of chemotherapy on tumor behavior and may influence treatment decisions for NSCLC patients.

Plain English
This study looked at how a drug called osimertinib works in patients with a specific type of lung cancer (NSCLC) that has a particular mutation (EGFR T790M). Among 50 patients, the researchers found that 72% experienced disease progression, but a significant number (73%) had progression in only a few places, which is called oligo-progression. This is important because patients with oligo-progression could continue to benefit from osimertinib for longer, and some even improved with additional targeted treatment on the areas that progressed. Who this helps: Patients with EGFR T790M-positive lung cancer may have better outcomes with continued treatment options.

Plain English
Researchers from Swiss hospitals studied how different doctors agree on diagnosing and treating head and neck cancer. They found that there was some level of agreement on treatment practices only 62% of the time, with specific areas like Medical Oncology having 83% agreement while Head and Neck Surgery had only 50%. This matters because the lack of consensus can lead to inconsistent patient care and highlights the need for clearer guidelines and future research on effective treatments. Who this helps: This benefits patients and healthcare providers by aiming for more standardized treatment approaches.

Plain English
This study looked at how doctors in Switzerland agree on diagnosing and treating head and neck cancer. Researchers found that there was a general agreement on treatment for only 62% of the topics, with high consensus on just 18%, while other areas had low to moderate agreement. This matters because inconsistencies in treatment can lead to varied patient outcomes and highlight the need for standardized care practices. Who this helps: This helps patients and their healthcare providers by promoting more consistent treatment approaches.

Plain English
The Swiss Group for Clinical Cancer Research studied how consistently doctors agree on the diagnosis and treatment of head and neck cancer across different hospitals. They found that doctors reached agreement less than half the time on various surgical and radiation oncology topics, with only 62% of topics showing any level of consensus. This matters because identifying areas of disagreement can help improve treatment standards and guide future research to enhance patient care. Who this helps: Patients with head and neck cancer.

Plain English
This study looked at how doctors in Switzerland agree on the diagnosis and treatment of head and neck cancer. Researchers surveyed ten hospitals and found that there was agreement on clinical topics only about 62% of the time, with high agreement in 18% of cases, moderate in 20%, and low in 23%. The findings indicate that there is significant disagreement among healthcare providers, especially surgeons and radiation oncologists, which suggests a need for clearer treatment guidelines and further research. Who this helps: This helps patients with head and neck cancer by promoting more consistent care from their medical teams.

Plain English
This study looked at how a technology-based program can help adults who don’t get enough sleep and have slightly high blood pressure. Over six weeks, those in the program (11 adults) reported sleeping longer and had lower blood pressure compared to those who just kept their usual sleep habits (5 adults). Specifically, the intervention group increased their sleep and lowered their average daytime blood pressure readings significantly. Who this helps: This helps patients with short sleep duration and prehypertension or stage 1 hypertension.

Plain English
This study looked at 299 patients with testicular cancer in Switzerland, Austria, and Germany, assessing their baseline characteristics and treatment approaches. They found that 64.2% had seminoma, while 35.8% had non-seminoma, with patients' average age being 41 for seminoma and 31 for non-seminoma. A significant number of patients chose different treatment paths: 57.8% of stage I seminoma patients opted for active surveillance instead of chemotherapy, while 45.6% of stage I non-seminoma patients with high-risk disease received chemotherapy. Who this helps: This research benefits doctors and oncologists by providing essential data to guide treatment decisions for testicular cancer patients.

Plain English
This study looked at patients with a type of lung cancer (NSCLC) who have both ALK gene alterations and either EGFR or KRAS mutations to see how well they respond to targeted treatments called tyrosine kinase inhibitors (TKIs). Out of 14 patients, most with the ALK/KRAS mutation did not respond well to the drug crizotinib, with 86% showing resistance, while those with the ALK/EGFR mutation had mixed outcomes but also did not do as well as patients with only one mutation. Understanding these results is important because it highlights the challenges in treating these specific genetic combinations in lung cancer, which could help doctors make better treatment decisions. Who this helps: Patients with ALK-positive non-small cell lung cancer and their doctors.

Plain English
This study looked at why some cancer patients accept or decline support for emotional distress from mental health professionals. Researchers found that there are several barriers preventing patients from using these services, and understanding these factors can help improve communication between patients and oncologists. For instance, improving discussions around emotional support could lead to more patients who need help actually receiving it. Who this helps: This helps cancer patients who might be struggling with emotional distress and need support.

Plain English
Researchers looked at whether a new alert system helped doctors better record and refer patients with obesity for treatment. They found that documentation of obesity-related care doubled from 17% to 33% after the alert was used, but referrals to weight management programs only slightly improved from 1.3% to 2.8%. This matters because while the alert improved record-keeping, it did not significantly help patients actually access weight loss services. Who this helps: This helps patients struggling with obesity who need better access to weight management resources.

Plain English
This study explored whether listening to personal recordings of self-love messages could reduce feelings of anger. Over the course of 12 weeks, participants who did this saw their average anger scores drop significantly from 10.4 to 6.7. This matters because it shows that self-love practices can effectively help manage anger, which could be useful in settings like conflict resolution. Who this helps: This benefits individuals dealing with anger issues, including those in conflict resolution scenarios.

Plain English
This study focused on a specific type of lung cancer called RET rearranged non-small cell lung cancer (NSCLC) among European patients. Researchers examined nearly a thousand lung cancer patients and found RET gene rearrangements in 22 patients, which is about 2.2% of those studied, with most affected individuals being men and the average age at diagnosis being 62. This research is important because it helps identify the characteristics of a rare lung cancer subgroup that may differ from findings in other populations, particularly showing a higher number of smokers in this group than previously reported. Who this helps: This information benefits doctors and researchers working to understand and treat lung cancer.

Plain English
This study focused on how community health workers (CHWs) could help Puerto Rican youth in Chicago manage asthma better. While most participants had uncontrolled asthma and less than half were using their inhaled medications at the start, 67% of those who received visits from a CHW improved their inhaler technique by 18% compared to the control group after five months. Although the intervention did not significantly increase medication usage or reduce asthma triggers at home, it highlighted the importance of working closely with healthcare providers for success. Who this helps: This research benefits healthcare providers and both Puerto Rican youth and their families dealing with asthma.

Plain English
This study looked at patients with a specific type of lung cancer that has BRAF mutations, which occurs in about 2% of cases. Researchers tracked 35 patients who were treated with targeted drugs like vemurafenib and dabrafenib. They found that patients with the common V600E mutation lived an average of 25.3 months after starting treatment, while those with other mutations lived about 11.8 months. Overall, 53% of patients had a significant response to the treatment, and 85% experienced stable disease. Who this helps: This information benefits patients with BRAF-mutant lung cancer and their doctors by providing insights into effective treatments.

Plain English
This study looked at blood samples from 50 patients with advanced non-squamous lung cancer to identify specific microRNAs (tiny molecules that help regulate genes) that could predict how long patients might live after receiving treatment with a combination of drugs (bevacizumab and erlotinib, followed by chemotherapy). The researchers found that high levels of a specific microRNA called hsa-miR-29a were linked to a poorer survival rate, with only 54% of these patients alive after 10 months compared to 83% of those with lower levels of this microRNA. This information is important because it could help doctors choose more effective treatments and monitor how well they are working based on a patient's microRNA profile. Who this helps: This helps patients with advanced non-squamous lung cancer by providing potential insights for personalized treatment plans.

Plain English
This study looked at specific parts of the EGFR gene to find new biomarkers that predict how well patients with advanced non-small cell lung cancer (NSCLC) will respond to treatments with two drugs, bevacizumab and erlotinib. The researchers discovered that higher levels of a particular segment of the EGFR gene (exon 18) were linked to tumor shrinkage in patients, even those without the usual EGFR mutations, highlighting its potential as a reliable marker for treatment response. This finding is important because it could help doctors better tailor therapies for patients, improving their chances of successful treatment. Who this helps: This aids patients with non-small cell lung cancer and their doctors.

Plain English
This research paper looks at lung cancer, which causes around 1.4 million deaths each year, primarily among older people; most patients are diagnosed when the cancer is already advanced. Treatment options for two types of lung cancer, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), are discussed, especially focusing on newer therapies for advanced NSCLC and using specific tests to tailor treatments to individual patients. It also highlights malignant pleural mesothelioma, a rare but aggressive cancer linked to asbestos exposure, with an average survival time of just one year after diagnosis. Who this helps: This information benefits patients suffering from lung cancer and their doctors.

Plain English
This study looked at new cancer immunotherapy treatments that help the immune system fight cancer more effectively. It found that the first cancer vaccine, Sipuleucel-T, improved survival rates in prostate cancer patients, and the drug ipilimumab significantly helped patients with metastatic melanoma live longer and respond better to treatment. This matters because it shows that these immunotherapy methods could become essential in treating cancer in the future. Who this helps: This helps cancer patients, especially those with prostate cancer and melanoma.

Plain English
This study looked at the safety and tolerability of a drug called gefitinib, used along with radiation therapy or with chemotherapy (cisplatin) in patients with advanced non-small cell lung cancer that couldn’t be surgically removed. Out of 14 patients, none experienced severe lung damage from gefitinib when used with radiation alone, but 22% of those who received the combination of gefitinib, radiation, and chemotherapy had serious side effects. The findings show that while gefitinib combined with radiation is manageable, adding chemotherapy may increase side effects, making it important to understand how effective this treatment is for improving survival. Who this helps: This helps patients with advanced non-small cell lung cancer and their doctors in choosing treatment options.

Plain English
The study investigated a new treatment called Ec4-ETA'' that combines a specially designed protein with a toxin to target and kill cancer cells. Researchers found that this treatment was extremely effective, killing tumor cells in lab tests with very small amounts (less than 0.005 pmol/L) and significantly shrinking tumors in mice within 48 to 72 hours after administration. This is important because it shows that this new approach could lead to better cancer treatments that specifically target tumors with fewer side effects. Who this helps: This benefits cancer patients by offering a potential new therapy that may be more effective and less harmful than current treatments.

Plain English
This study looked at how well community health workers, known as promotoras, were trained to help Mexican Americans manage diabetes. It found that while initial training gave them a good foundation, ongoing training was essential for them to handle both work-related and personal challenges effectively. This is important because it shows that providing continuous support leads to better outcomes for patients managing their diabetes. Who this helps: This helps patients with diabetes, particularly in the Mexican American community, by ensuring they have knowledgeable support.

Plain English
This study looked at a 71-year-old man who had a long history of a skin growth in his ear called cholesteatoma, which led to the development of a rare form of cancer in his temporal bone. After multiple surgeries since 1950, he was diagnosed with moderately differentiated squamous cell carcinoma in 2004, and he received a specific type of radiation therapy. This case highlights the connection between chronic cholesteatoma and the risk of cancer, which is important for early detection and treatment strategies. Who this helps: This helps patients with chronic ear conditions and their doctors in understanding potential cancer risks.

Plain English
This study looked at how well external beam radiation therapy (RT) worked for 24 patients with AIDS-related lymphoma over a 9-year period. The findings showed that 65% of patients were still alive one year after treatment, and that number dropped to 35% after five years. Factors like the amount of radiation given and the patients' viral load were linked to their chances of survival, making it clear that combining RT with other treatments can be very effective. Who this helps: This helps patients with HIV and AIDS-related lymphoma, as well as their doctors.

Plain English
This study looked at how nurse coaches can help small medical offices adopt a new way of caring for patients called Virtual Integrated Practice (VIP). The researchers found that the use of nurse coaches was well-received, with high levels of acceptance, and that the VIP model was implemented to varying degrees across three different practices. This matters because it shows that nurse coaches can play a key role in improving care quality in smaller healthcare settings. Who this helps: Patients in small primary care practices.

Plain English
The research looked at bleeding problems in patients taking blood thinners to prevent strokes and blood clots. Out of 84 patients studied, there were 87 bleeding incidents, mostly in the gastrointestinal tract, with nearly half of these occurring after more than three years of treatment. The findings highlight that while age doesn't affect the severity of bleeding complications, older patients often experience these complications later in their treatment, stressing the need for careful monitoring and management of blood thinners over time. Who this helps: This helps doctors and healthcare providers manage treatment plans for patients on anticoagulants.

Plain English
This study looked at five patients over the age of 50 who were diagnosed with Ewing's sarcoma family tumors and how they responded to treatment. While four of these patients achieved complete remission, all experienced significant side effects that required treatment adjustments. One patient sadly passed away from complications, highlighting the challenges of using standard treatments from younger patients on older adults with this type of cancer. Who this helps: This research provides insights that can help doctors better tailor treatment plans for older patients with Ewing's sarcoma family tumors.

Plain English
This study looked at two different ways to treat a condition called vaginismus, which makes vaginal penetration painful or impossible. Researchers compared 16 women who received therapy with a male surrogate partner to 16 women who did the therapy with their own partners. They found that 100% of the women treated with a surrogate were able to have pain-free intercourse, while only 75% of the women with their partners achieved the same result. This is important because it shows that using a surrogate can be a highly effective option for women who don't have a supportive partner. Who this helps: This helps women with vaginismus, particularly those without a cooperative partner.

Plain English
This study looked at how using a special imaging technique called PET/CT along with a targeted radiation treatment called IMRT affects people with advanced throat cancer. Researchers found that patients who received PET/CT and IMRT had a 97% survival rate after one year and 91% after two years, compared to 74% and 54% for those who did not use these methods. This matters because it shows a significant improvement in patient outcomes, suggesting that these treatments can help more people survive and stay cancer-free longer. Who this helps: Patients with advanced pharyngeal cancer.

Plain English
This study looked at how effective human dental pulp (the tissue inside teeth) is for obtaining DNA that can be used for identification purposes in both research and forensic cases. The researchers found that DNA could be recovered from dental pulp in amounts ranging from 6 to 50 micrograms, even after the teeth had been stored for several years. This is important because it shows that dental pulp can provide useful DNA for identifying individuals, particularly in situations where other sources may be degraded or unavailable. Who this helps: This helps forensic scientists and law enforcement solve cases involving unidentified remains.